봄철 각결막염 시장 기회, 성장 촉진요인, 산업 동향 분석 및 예측(2025-2034년)

The Global Vernal Keratoconjunctivitis Market was valued at USD 426.2 million in 2024 and is estimated to grow at a CAGR of 5.5% to reach USD 720.1 million by 2034.

VKC primarily affects children and adolescents, particularly in warm climates. The growing awareness and diagnosis of allergic ocular conditions in this demographic are driving demand for effective VKC treatments globally.

Increasing Prevalence of Limbal Vernal Keratoconjunctivitis

The limbal vernal keratoconjunctivitis segment held a sizeable share in2024, backed by gelatinous limbal infiltrates and potential damage to the corneal epithelium. This segment is gaining clinical attention due to its tendency to cause long-term complications if left untreated. It is particularly common in children living in warm, dry climates, which heightens the demand for targeted therapies in endemic regions.

Mast Cell Stabilizers to Gain Traction

The mast cell stabilizers segment generated robust revenues in 2024 for patients with mild to moderate symptoms. These agents work by preventing the release of histamines and other inflammatory mediators, helping to reduce itching, redness, and swelling. Though they often require several weeks to reach full efficacy, their favorable safety profile makes them a preferred first-line option. To stay competitive, pharmaceutical companies are enhancing formulations for faster onset of action, combining mast cell stabilizers with antihistamines, and improving dosing convenience to support patient adherence.

Rising Adoption of Topical Treatments

The topical treatments segment held a significant share in 2024, owing to their direct mode of action and minimal systemic exposure. Eye drops containing corticosteroids, cyclosporine, tacrolimus, and antihistamines are widely prescribed to manage acute flare-ups and chronic inflammation. This segment benefits from continuous innovation in drug delivery technologies, such as sustained-release formulations and preservative-free options.

North America to Emerge as a Propelling Region

North America vernal keratoconjunctivitis market held a robust share in 2024 owing to improved diagnostic rates, heightened awareness among eye care professionals, and increasing cases linked to climate shifts and allergens. The region also benefits from a well-established ophthalmic drug industry and regulatory pathways that support innovation in pediatric care.

Major players in the vernal keratoconjunctivitis market are Santen Pharmaceutical, Teva Pharmaceuticals, Meda Pharmaceuticals, Novartis, Bausch Health, Senju Pharmaceutical, Allergan, Sun Pharma, F Hoffmann La Roche, Laboratoires Thea, AbbVie, Alcon, and Abbott Laboratories.

To build a strong presence in the vernal keratoconjunctivitis market, companies are deploying multi-layered strategies centered around product differentiation, clinical validation, and targeted outreach. Key initiatives include investing in pediatric clinical trials, securing regulatory exclusivity for rare disease indications, and launching educational campaigns for early diagnosis.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Data mining sources
  • 1.3.1 Global
  • 1.3.2 Regional/country
• 1.4 Base estimates and calculations
  • 1.4.1 Base year calculation
  • 1.4.2 Key trends for market estimation
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
• 1.6 Forecast model
• 1.7 Research assumption and limitations

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis
• 2.2 Key market trends
  • 2.2.1 Regional trends
  • 2.2.2 Disease type trends
  • 2.2.3 Treatment trends
  • 2.2.4 Route of administration trends
  • 2.2.5 Gender trends
  • 2.2.6 Distribution channel trends
• 2.3 CXO perspectives: Strategic imperatives
  • 2.3.1 Key decision points for industry executives
  • 2.3.2 Critical success factors for market players
• 2.4 Future outlook and strategic recommendations

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
  • 3.1.1 Supplier landscape
  • 3.1.2 Value addition at each stage
  • 3.1.3 Factor affecting the value chain
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising global prevalence of vernal keratoconjunctivitis
    • 3.2.1.2 Growing aging population and rising allergy sensitivity
    • 3.2.1.3 Expansion of tele-ophthalmology and e-pharmacy
    • 3.2.1.4 Government and institutional awareness programs
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost of branded immunomodulators and biologics
    • 3.2.2.2 Limited awareness and diagnostic capabilities in rural areas
  • 3.2.3 Market opportunities
    • 3.2.3.1 Development of combination and steroid-sparing therapies
    • 3.2.3.2 Emerging markets with rising healthcare investment
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
  • 3.4.1 North America
    • 3.4.1.1 U.S.
    • 3.4.1.2 Canada
  • 3.4.2 Europe
  • 3.4.3 Asia Pacific
• 3.5 Future market trends
• 3.6 Technology landscape
• 3.7 Pricing analysis
• 3.8 Pipeline analysis
• 3.9 Porter's analysis
• 3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company market share analysis
  • 4.2.1 Global
  • 4.2.2 North America
  • 4.2.3 Europe
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Merger and acquisition
  • 4.6.2 Partnership and collaboration
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Disease Type, 2021 - 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Limbal vernal keratoconjunctivitis
• 5.3 Tarsal vernal keratoconjunctivitis
• 5.4 Mixed vernal keratoconjunctivitis

Chapter 6 Market Estimates and Forecast, By Treatment, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Mast cell stabilizers
• 6.3 Antihistamines
• 6.4 Corticosteroids
• 6.5 Nonsteroidal anti-inflammatory drugs
• 6.6 Other treatments

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Oral
• 7.3 Topical
• 7.4 Parenteral

Chapter 8 Market Estimates and Forecast, By Gender, 2021 - 2034 ($ Mn)

• 8.1 Key trends
• 8.2 Male
• 8.3 Female

Chapter 9 Market Estimates and Forecast, By Distribution Channel, 2021 - 2034 ($ Mn)

• 9.1 Key trends
• 9.2 Hospital pharmacies
• 9.3 Retail pharmacies
• 9.4 Online pharmacies

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

• 10.1 Key trends
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Spain
  • 10.3.5 Italy
  • 10.3.6 Netherlands
• 10.4 Asia Pacific
  • 10.4.1 China
  • 10.4.2 Japan
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 South Korea
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Argentina
• 10.6 Middle East and Africa
  • 10.6.1 South Africa
  • 10.6.2 Saudi Arabia
  • 10.6.3 UAE

Chapter 11 Company Profiles

• 11.1 Abbott Laboratories
• 11.2 AbbVie
• 11.3 Alcon
• 11.4 Allergan
• 11.5 Bausch Health
• 11.6 F Hoffmann La Roche
• 11.7 Laboratoires Thea
• 11.8 Meda Pharmaceuticals
• 11.9 Novartis
• 11.10 Santen Pharmaceutical
• 11.11 Senju Pharmaceutical
• 11.12 Sun Pharmaceutical